KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Receivables (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Receivables for 12 consecutive years, with $81.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 176.84% year-over-year to $81.4 million, compared with a TTM value of $81.4 million through Dec 2025, up 176.84%, and an annual FY2025 reading of $81.4 million, up 176.84% over the prior year.
  • Receivables was $81.4 million for Q4 2025 at Travere Therapeutics, down from $84.5 million in the prior quarter.
  • Across five years, Receivables topped out at $84.5 million in Q3 2025 and bottomed at $11.9 million in Q2 2021.
  • Average Receivables over 5 years is $28.1 million, with a median of $23.2 million recorded in 2023.
  • The sharpest move saw Receivables decreased 27.62% in 2021, then soared 205.38% in 2025.
  • Year by year, Receivables stood at $16.8 million in 2021, then grew by 10.3% to $18.5 million in 2022, then surged by 39.0% to $25.8 million in 2023, then rose by 14.11% to $29.4 million in 2024, then skyrocketed by 176.84% to $81.4 million in 2025.
  • Business Quant data shows Receivables for TVTX at $81.4 million in Q4 2025, $84.5 million in Q3 2025, and $40.2 million in Q2 2025.